A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)